Stocks · News reference
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial
The European Commission has granted Orphan designation to Solid Biosciences' SGT-212 for the treatment of Friedreich's ataxia, while the company reports continued progress in its Phase 1b FALCON clinical trial.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20
This Brinker Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Neutral on MCD; Buy on MOVE and EAT; Outperform on SLDB; Equal-Weight on GOLF, with price targets announced.